Triple drug therapy for new PAH patients
Part of Lungs & breathing clinical trials.
This trial tests whether a combination of three medications works well and is safe for people newly diagnosed with pulmonary arterial hypertension (PAH) that is not low-risk. It aims to see if starting with triple therapy early can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have pulmonary arterial hypertension (PAH) that is not considered low-risk.
- You must never have taken any PAH medication before.
- You cannot have had a positive acute vasoreactivity test (a test that checks how your lungs respond to a drug).
- You cannot be pregnant or breastfeeding.
- You cannot have certain other serious health problems like advanced liver or kidney disease, severe anemia, or active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares starting treatment with three medicines, including a continuous infusion (treprostinil), versus two oral medicines for people newly diagnosed with moderate-to-high risk pulmonary arterial hypertension (PAH). The goal is to see which approach improves heart function and symptoms more effectively.
This trial tests a new combination of three medicines (including an experimental drug called sotatercept) for people recently diagnosed with PAH. The goal is to see if this early, powerful treatment works better than standard care in improving heart and lung function.
This study compares two approaches for people with PAH whose current treatment (a combination of sildenafil and an endothelin receptor antagonist) needs to be stepped up. Half the participants will add a third medicine (iloprost or selexipag), while the other half will increase their sildenafil dose. The goal is to see which strategy works better for improving symptoms and lowering risk.
This study compares starting with one medication versus two medications together for people with pulmonary arterial hypertension (PAH). It aims to find out which approach works better for low- or intermediate-risk patients.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This study tests a drug called treprostinil to see if it is safe and effective for people with intermediate-risk pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. If you join, you may receive the study drug along with your usual PAH medications, which could help improve your symptoms and slow the disease.
Hear when a new Arterial Pulmonary Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.